The U.S. Food and Drug Administration (FDA) approved a supplemental application for atezolizumab, marketed as Tecentriq, on December 3, 2019. This approval specifically addresses the drug's efficacy, indicating an expansion or modification of its approved uses. The application was sponsored by Genentech Inc.
Background
Atezolizumab (Tecentriq) is an established therapeutic agent. The FDA's action on this supplemental application confirms an update to the drug's efficacy profile. Such supplemental approvals are granted when new data supports an expansion of a drug's approved indications, a new patient population, or a change in dosing or administration based on demonstrated efficacy.
What this means
This supplemental approval for atezolizumab (Tecentriq) provides updated information regarding its efficacy, which is important for healthcare providers and patients. While the specific details of the expanded indication or population are not provided in the source data, this type of approval generally broadens the scope of conditions or patient groups for which the drug can be prescribed. Clinicians should consult the updated prescribing information for Tecentriq to understand the full implications of this efficacy-based approval.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on December 3, 2019. The details are publicly available on the FDA's accessdata.fda.gov website, under application number BLA761034 S-21.